adlitterio66339

About adlitterio66339

This author has not yet filled in any details.
So far adlitterio66339 has created 715 blog entries.

6 03, 2025

Shooting Cancer Highlights – Periodic focus on regulatory status of new targeted therapies in oncology

adlitterio663392025-03-06T10:14:19+01:00

1 03, 2025

Veronica Agostinelli et al., The Impact and Performance of the Molecular Tumor Board: Three-Year Activity in Precision Medicine for Treatment of Patients with Cancer from the Marche Region, in Italy

adlitterio663392025-03-01T15:12:42+01:00

18 02, 2025

HAL?M ÖZÇEV?K ET AL., Genetic mutations and prognostic indicators in differentiated thyroid cancer: a molecular perspective

adlitterio663392025-02-18T15:21:35+01:00

15 02, 2025

Robrto Montalti et al., Prognostic role of postoperative persistence of ctDNA molecular signature after liver resection for colorectal liver metastases: Preliminary results from a prospective study

adlitterio663392025-02-15T15:19:51+01:00

13 02, 2025

Orhan Gorukmez et al., RNA-based next-generation sequencing approach to non-small cell lung cancer: A single center experience in Turkey

adlitterio663392025-02-13T15:18:00+01:00

13 02, 2025

Seda Er Özilhan et al., Correlation of PD-L1 and HIF-1 Alpha Expression with KRAS Mutation and Clinicopathological Parameters in Non-Small Cell Lung Cancer

adlitterio663392025-02-13T15:14:58+01:00

28 01, 2025

Fahmideh Bagrezaei et al., Assessment of the quality of life in metastatic colorectal cancer patients with KRAS gene mutant: a case-control study

adlitterio663392025-01-28T15:10:34+01:00

27 01, 2025

Elisabetta Maffei et al., Suitability of Different Cytological Preparations for Molecular Analysis of Advanced Non-Small Cell Lung Cancers

adlitterio663392025-01-27T15:07:22+01:00

16 01, 2025

Francesca Pagani et al., Concurrent RB1 and P53 pathway disruption predisposes to the development of a primitive neuronal component in high-grade gliomas depending on MYC-driven EBF3 transcription

adlitterio663392025-01-16T15:01:25+01:00

10 01, 2025

Shooting Cancer Highlights – Periodic focus on regulatory status of new targeted therapies in oncology

adlitterio663392025-01-10T15:00:06+01:00